708 related articles for article (PubMed ID: 17509328)
41. Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions.
Klaphajone J; Kitisomprayoonkul W; Sriplakit S
Arch Phys Med Rehabil; 2005 Nov; 86(11):2114-8. PubMed ID: 16271557
[TBL] [Abstract][Full Text] [Related]
42. Duloxetine compared with placebo for treating women with symptoms of overactive bladder.
Steers WD; Herschorn S; Kreder KJ; Moore K; Strohbehn K; Yalcin I; Bump RC;
BJU Int; 2007 Aug; 100(2):337-45. PubMed ID: 17511767
[TBL] [Abstract][Full Text] [Related]
43. Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity.
Schmid DM; Roy S; Sulser T; Scheiner D
BJU Int; 2008 Jul; 102 Suppl 1():7-10. PubMed ID: 18665972
[TBL] [Abstract][Full Text] [Related]
44. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients.
Mascarenhas F; Cocuzza M; Gomes CM; Leão N
Neurourol Urodyn; 2008; 27(4):311-4. PubMed ID: 17914742
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
[TBL] [Abstract][Full Text] [Related]
46. Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units.
Cohen BL; Barboglio P; Rodriguez D; Gousse AE
Neurourol Urodyn; 2009; 28(3):205-8. PubMed ID: 19058190
[TBL] [Abstract][Full Text] [Related]
47. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?
Kuo HC
Urology; 2006 Nov; 68(5):993-7; discussion 997-8. PubMed ID: 17113890
[TBL] [Abstract][Full Text] [Related]
48. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
Nitti VW; Rovner ES; Bavendam T
BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
[TBL] [Abstract][Full Text] [Related]
49. [Botulinum toxin type A in patients with overactive bladder].
Krivoborodov GG; Vasil'ev AV; Shumilo DV; Ivanov AV; Tur EI
Urologiia; 2010; (3):36-40. PubMed ID: 20734876
[TBL] [Abstract][Full Text] [Related]
50. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
[TBL] [Abstract][Full Text] [Related]
51. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence.
Schurch B; Denys P; Kozma CM; Reese PR; Slaton T; Barron RL
Eur Urol; 2007 Sep; 52(3):850-8. PubMed ID: 17467889
[TBL] [Abstract][Full Text] [Related]
52. Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity.
Bach P; Wormland RT; Möhring C; Goepel M
Neurourol Urodyn; 2009; 28(3):209-13. PubMed ID: 19205067
[TBL] [Abstract][Full Text] [Related]
53. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.
Reitz A; Stöhrer M; Kramer G; Del Popolo G; Chartier-Kastler E; Pannek J; Burgdörfer H; Göcking K; Madersbacher H; Schumacher S; Richter R; von Tobel J; Schurch B
Eur Urol; 2004 Apr; 45(4):510-5. PubMed ID: 15041117
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study.
Werner M; Schmid DM; Schüssler B
Am J Obstet Gynecol; 2005 May; 192(5):1735-40. PubMed ID: 15902187
[TBL] [Abstract][Full Text] [Related]
55. Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going.
Sahai A; Khan MS; Gregson N; Smith K; Dasgupta P;
Nat Clin Pract Urol; 2007 Jul; 4(7):379-86. PubMed ID: 17615549
[TBL] [Abstract][Full Text] [Related]
56. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction.
Schulte-Baukloh H; Weiss C; Stolze T; Herholz J; Stürzebecher B; Miller K; Knispel HH
Eur Urol; 2005 Dec; 48(6):984-90; discussion 990. PubMed ID: 16126328
[TBL] [Abstract][Full Text] [Related]
57. [Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder].
Bentaleb Y; Castel-Lacanal E; Sallusto F; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
Prog Urol; 2008 Jul; 18(7):449-55. PubMed ID: 18602606
[TBL] [Abstract][Full Text] [Related]
58. Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity.
Kalsi V; Apostolidis A; Gonzales G; Elneil S; Dasgupta P; Fowler CJ
Eur Urol; 2008 Jul; 54(1):181-7. PubMed ID: 18191323
[TBL] [Abstract][Full Text] [Related]
59. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience.
Rapp DE; Lucioni A; Katz EE; O'Connor RC; Gerber GS; Bales GT
Urology; 2004 Jun; 63(6):1071-5. PubMed ID: 15183952
[TBL] [Abstract][Full Text] [Related]
60. [Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].
Chenet A; Perrouin-Verbe B; Le Normand L; Labat JJ; Brunel P; Lefort M; Mathé JF
Ann Readapt Med Phys; 2007 Nov; 50(8):651-60. PubMed ID: 17490775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
